Repertoire Immune Medicines


Clinical-stage biotechnology company developing T cell-targeted immune medicines for cancer and autoimmune diseases. The company operates an integrated platform that maps the immune synapse at scale, applies AI to predict TCR–epitope recognition, and engineers therapeutic modalities including engineered TCR bispecific molecules and mRNA-based vaccines and tolerizing therapies. Operates sites in Watertown, MA (US) and Zurich/Schlieren (Switzerland).

Industries

Biotechnology
Life Science
Medical
Therapeutics
Biotech & Pharmaceuticals
Pharmaceutical and biotechnology
Biotechnology Research

Nr. of Employees

medium (51-250)

Repertoire Immune Medicines

Cambridge, Massachusetts, United States


Products

RPTR-1-201

Engineered TCR bispecific molecule targeting a shared tumor-selective epitope; evaluated as monotherapy and in combination with anti-PD-1 therapy in a Phase 1/2 clinical trial for advanced solid tumors.

RPTR-1-301

TCR bispecific program in IND-enabling stage targeting HPV-associated cancers and related tumor types.

Lead optimization-stage TCR programs (multiple targets)

Multiple TCR bispecific lead optimization programs across tumor indications including prostate, TNBC, melanoma and other solid tumors.

mRNA tolerizing therapy programs (lead optimization)

mRNA-encoded tolerizing therapy programs encoding disease-relevant epitopes and immune modulators formulated in lipid nanoparticles for autoimmune disease indications; programs in lead optimization.

Expertise Areas

  • Immune synapse mapping and TCR–epitope discovery
  • TCR-based biologic engineering (bispecifics)
  • mRNA therapeutics and LNP delivery
  • AI-driven target discovery and generative design
  • Show More (4)

Key Technologies

  • T cell receptor (TCR) bispecific molecules
  • mRNA vaccines and tolerizing therapeutics
  • Lipid nanoparticle (LNP) formulation
  • Peptide–MHC library screening
  • Show More (6)

News & Updates

U.S. FDA granted Fast Track designation to RPTR-1-201 for treatment of HLA-A*02:01-positive adults with unresectable or metastatic triple-negative breast cancer after progression on or intolerance to available therapies.

First participant dosed in a Phase 1/2 trial evaluating safety, tolerability, and preliminary antitumor activity of an engineered TCR bispecific molecule in adults with advanced solid tumors; IND cleared by FDA and CTIS authorization in Europe.

Entered strategic collaboration with Eli Lilly to co-develop tolerizing therapies for multiple autoimmune diseases; agreement includes upfront payment and milestone and royalty provisions.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.